On March 10, 2021 LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, reported that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of the virtual American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which will be held April 10-15, 2021 (Press release, Lava Therapeutics, MAR 10, 2021, View Source [SID1234576429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following abstract is now available on the AACR (Free AACR Whitepaper) website at www.aacr.org.

Title: Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Session Type: E-Poster Session
Session Title: Therapeutic Antibodies, Including Engineered Antibodies
Abstract Number: 1855

LAVA-051 is a humanized gamma-delta bsTCE which targets CD1d and the Vδ2 domain of the T cell receptor. It is the first antibody-based compound targeting CD1d to activate both Vγ9Vδ2-T and type 1 NKT cells. LAVA-051 exerted substantial antitumor activity against patient derived acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells that express CD1d. In addition, improved survival was observed in in vivo AML and MM mouse xenograft models treated with LAVA-051.

LAVA-051 is planned to enter a Phase I/IIa study in hematologic malignancies in 1H 2021.

On March 10, 2021 Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that it will release its fourth quarter and full-year 2020 financial results before U.S. financial markets open on Thursday, March 18, 2021 (Press release, Legend Biotech, MAR 10, 2021, View Source [SID1234576428]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Legend Biotech will conduct a conference call to discuss those results on March 18, 2021 at 8:00 am ET. To listen to the call via webcast visit Legend Biotech’s website at View Source." target="_blank" title="View Source." rel="nofollow">View Source To listen to the call via telephone dial (833) 665-0666 from locations in the United States or (914) 987-7318 from outside the United States. Please refer to conference ID number 2677312.

A replay of the webcast will be available on the "Events and Presentations" page within the Investors section of the website at View Source for 90 days following the conference call.

On March 10, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported multiple presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, including three oral presentations to highlight clinical data on anti-PD-1 antibody tislelizumab and on investigational spectrum-selective kinase inhibitor sitravatinib in combination with tislelizumab, and one poster presentation of preclinical data on its investigational anti-TIGIT antibody ociperlimab (BGB-A1217) (Press release, BeiGene, MAR 10, 2021, View Source [SID1234576427]). The AACR (Free AACR Whitepaper) Annual Meeting will take place in a virtual format on April 10-15 and May 17-21, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations:

Title:

Results from RATIONALE 303: A global Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC

Presentation #:

CT039

Session Title:

Disease-Oriented Innovative Clinical Research and Trials

Date and Time:

Monday, April 12, 2021 at 1:30 – 3:15 p.m. ET

Presenter:

Professor Caicun Zhou, Shanghai Pulmonary Hospital, China

Title:

Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)

Presentation #:

CT013

Session Title:

Targeted Therapy and Ovarian Cancer Trials

Date and Time:

Sunday, April 11, 2021 at 2:00 – 3:45 p.m. ET

Presenter:

Jeffrey Goh, MBBS, FRACP, Icon Cancer Centre, Australia

Title:

Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study

Presentation #:

CT035

Session Title:

Clinical Trials with Novel Immuno-Oncology Strategies

Date and Time:

Sunday, April 11, 2021 at 4:00 – 5:45 p.m. ET

Presenter:

Professor Chuanliang Cui, Beijing Cancer Hospital, China

On March 10, 2021 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported the planned presentation of two posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting I, taking place April 10-15, 2021 (Press release, Alpine Immune Sciences, MAR 10, 2021, View Source [SID1234576426]). Dr. Mark Voskoboynik of Nucleus Network and The Alfred Hospital in Melbourne, Australia, will be presenting a poster in the Phase 1 Clinical Trials in Progress session on NEON-1, a Phase I study of ALPN-202 in advanced malignancies. Separately, Alpine researchers will present a preclinical poster describing the application of Alpine’s directed evolution platform to the development of fusion proteins capable of tumor antigen-dependent CD28 costimulation, as a distinctive immuno-oncology approach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentations are as follows:

Presentation Title: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Session Category: Phase I Clinical Trials in Progress
Session Title: Phase I Clinical Trials in Progress
Date Poster Available: Saturday, April 10th
Session Type: E-Poster Session
Poster Number: CT213
Presentation Title: Engineered variant domain fusion proteins provide checkpoint inhibition and tumor antigen dependent CD28 costimulation resulting in potent anti-tumor immunity

Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions
Date Poster Available: Saturday, April 10th
Session Type: E-Poster Session
Poster Number: 1740
Titles and/or full abstracts are available on the AACR (Free AACR Whitepaper) Virtual Annual Meeting website. Posters for both presentations will be available on the Scientific Publications page of Alpine’s website on April 10th.

About ALPN-202

ALPN-202 is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor designed to improve upon the efficacy of combined checkpoint inhibition while limiting significant toxicities. Preclinical studies of ALPN-202 demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. NEON-1 (NCT04186637), a Phase 1 study of ALPN-202 in patients with advanced malignancies, is currently enrolling.

On March 10, 2021 Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, reported that it has obtained a term loan facility from Hercules Capital (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences market (Press release, Humanigen, MAR 10, 2021, View Source [SID1234576425]). Under the terms of the facility, Hercules will provide Humanigen up to $80 million of secured debt financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The term loan facility provides working capital to support the production of lenzilumab, strengthens our balance sheet and increases our financial flexibility as we prepare for the potential Emergency Use Authorization and commercial launch of lenzilumab in 2021," said Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.

The facility consists of a $25 million initial term loan, with up to an additional $55.0 million available for future draws subject to achievement of future milestones and satisfaction of other conditions. The facility provides for an interest-only period and the four-year term is extendable under certain conditions. Loans under the facility are secured by the company’s assets.

"Hercules is excited to be partnering with Humanigen as it advances lenzilumab for COVID-19 and other indications. This structured financing represents a significant commitment from Hercules, which is consistent with our goal of supporting innovative life sciences companies," said Himani Bhalla, Principal at the Life Sciences group at Hercules. "This is an example of the breadth of our platform and our ability to finance life sciences companies through all stages of development."